Equitable Trust Co. Has $1.13 Million Stock Position in ICU Medical, Inc. $ICUI

Equitable Trust Co. lifted its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 59.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 8,538 shares of the medical instruments supplier’s stock after buying an additional 3,196 shares during the period. Equitable Trust Co.’s holdings in ICU Medical were worth $1,128,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC increased its stake in shares of ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 153 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of ICU Medical during the 1st quarter worth $859,000. Vontobel Holding Ltd. acquired a new position in shares of ICU Medical during the 1st quarter worth $235,000. EP Wealth Advisors LLC acquired a new position in shares of ICU Medical during the 1st quarter worth $479,000. Finally, Vident Advisory LLC acquired a new position in shares of ICU Medical during the 1st quarter worth $270,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Activity

In other ICU Medical news, CEO Vivek Jain purchased 21,929 shares of the stock in a transaction dated Thursday, August 14th. The stock was bought at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the transaction, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David C. Greenberg purchased 1,200 shares of the stock in a transaction dated Wednesday, August 27th. The shares were acquired at an average price of $126.42 per share, with a total value of $151,704.00. Following the transaction, the director owned 7,960 shares in the company, valued at $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ICUI. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Piper Sandler raised their target price on shares of ICU Medical from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 5th. Finally, Raymond James Financial lowered their target price on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average target price of $181.00.

ICU Medical Price Performance

NASDAQ:ICUI opened at $117.31 on Wednesday. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $196.26. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -77.18 and a beta of 0.83. The company has a 50-day moving average of $123.82 and a 200-day moving average of $130.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.66. The firm had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm’s quarterly revenue was down 8.0% on a year-over-year basis. During the same period last year, the firm posted $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities research analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.